Monday, 25 May 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 25 May 2026
News

Next-gen drug beats expectations

Posted 25 May 2026 AM

There were sky-high expectations for Eli Lilly's triple-agonist obesity drug, but the latest results have surpassed them and given the pharma ammunition in its late-stage pipeline to dominate the obesity market.

Participants in the TRIUMPH-1 trial who were taking 12mg of retatrutide weekly as a subcutaneous injection lost an average of 28.3 per cent of their body weight over 80 weeks, and 45.3 per cent of participants achieved more than 30 per cent weight loss.

To see the whole article, please login

Popular

Ninth time a Great Place To Work
Ex-Google boss busts pharma silos
Highest paid KOLs revealed
How much MSLs really earn
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home